1. HBW Insight
  2. >>Wellness
  4. >>Earnings

GSK Raises Product Prices in US And Europe As Costs Rise

 
• By Tom Gallen

GSK revealed price increases in the US, Europe and China as it posted Q3 sales up high single-digits, with gains in key categories such as pain relief and vitamins, minerals and supplements.

arrows pointing upwards
• Source: Alamy

GlaxoSmithKline Consumer Healthcare is rolling out product price increases around the globe in a response to further pressure from cost inflation.

Speaking as London-based GSK reported its third-quarter results, Consumer Healthcare CEO Brian McNamara said like many of its peers the firm was raising prices in the US, Europe and Asia, in

Earlier this month, GSK had raised prices in the US in the mid-to-high single digit range, McNamara revealed, on brands that represented approximately 50% of its sales in the market, including the Sensodyne

More from Earnings

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By Tom Gallen

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

More from Business